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I 
n  this issue  of the Journal of ExperimentaI Medicine,  Loet- 
scher et al. show that receptors for ~-chemokines are up- 
regulated  when  T  lymphocytes are  activated by interleu- 
kin-2  (1).  This paper will  be of considerable  interest not 
just to those who have worked for some years to identify 
conditions whereby chemokines could  attract T  ceils,  but 
also to HIV researchers and conceivably to retrovirologists 
in  general.  It  is  not  often  that  two  seemingly  unrelated 
fields,  chemotaxis and  retroviral infection,  meld to  create 
an entire new area of research, but that is exactly what has 
happened over the past six months. 
For several years, it has been known that CD8 §  T  ceils 
secrete factors that suppress HIV-1 replication in CD4 + T 
cells  (2-4).  The  nature  of these  factors remained  elusive, 
however, until  December of last  year when Cocchi et al. 
showed  that  the  [3-chemokines  MIP-lci,  MIP-I[3,  and 
RANTES contributed to the CD8+-cell suppressive effect 
(5). It is probable that these ~-chemokines are not the only 
components of CD8 + cell conditioned medium that have 
an anti-viral effect against HIV-1, but it is certain that they 
are important components of the cocktail. 
It has  also  been known,  for over a  decade in  this  case, 
that  HIV-1  needs  a  species-specific (but not  cell lineage- 
specific) accessory fusion factor (second receptor)  to  enter 
CD4 + cells  (6-8). The expression of CD4 is necessary, but 
not  sufficient,  for efficient  HIV-1  replication.  In  the  ab- 
sence of the second receptor, HIV-1 can bind to its target 
cells  (via CD4), but the fusion process is not initiated  (6). 
The  identity  of the  second  receptor  remained  unknown 
despite much searching by many research groups. The log- 
jam in this field was finally broken in April of this year by 
the  publication of a paper from Ed Berger's group at the 
National  Institutes of Health showing that the second re- 
ceptor  for  at  least  some  strains  of HIV-1  was  LESTR 
(fusin),  a member of the same receptor superfamily as the 
~-chemokine receptors (9). 
The inhibitory effects ofMIP-lot, MIP-I~, and RANTES 
are largely restricted to primary, NSI strains of HIV-1  (5, 
10).  However, LESTR was clearly shown to be the second 
receptor for strains of HIV-1 adapted to growth in perma- 
nent  cell lines  (TCLA strains)  and primary viruses of the 
more aggressive, SI phenotype (9). Furthermore, LESTR is 
not  known  to  be  a  ~-chemokine  receptor;  indeed,  its 
physiological ligand  is  presently unknown  (9,  11).  These 
discrepancies  notwithstanding,  the  potential  connection 
between Berger's paper and that ofCocchi et al. did not go 
unappreciated by many research groups (5, 9). 
The  [3-chemokine  receptors  are  from the  seven  trans- 
membrane-spanning, G-protein-coupled superfamily (12- 
16).  Dozens of these receptors are encoded by the human 
genome,  and they bind a range of ligands, including pep- 
tide  hormones,  neuropeptides  and  the  et- and  ~-chemo- 
kines.  Other members of the receptor superfamily are in- 
volved  in  vision,  taste,  and  smell  perception.  As  the 
superfamily name  suggests,  the  receptors  span  the  plasma 
membrane seven times, so that about half of the protein is 
buried in the membrane. The extracellular domains, espe- 
cially the  NH  2 terminus,  are  involved in  ligand  binding, 
the intraceilular regions in coupling to the effector systems 
of signal transduction pathways, via G-proteins (12-16). 
Several groups commenced a search for a ~3-chemokine 
receptor that  could  serve  as  the  second  receptor for pri- 
mary, NSI strains of HIV-1. It did not take long for the re- 
cently published  CKR-5  receptor  (17)  to be identified  as 
an HIV-1 second receptor (18,  19).  CKR-5 appears to be 
the counterpart of LESTR for NSI primary viruses, and its 
second receptor functions are inhibited  by ~-chemokines. 
Thus, [3-chemokines inhibit HIV-1 replication by blocking 
the  fusion  of the  virus  with  its  target  cell,  perhaps  by a 
competitive interaction with the receptor (18).  In addition, 
it has been shown that CD4 +  T  cells  from some persons 
who have been multiply exposed to HIV-1 yet remain un- 
infected  (EU  individuals)  are  incompetent  at  fusing  with 
NSI HIV-1 strains (18).  The defect in the EU cells may lie 
at the level of the CKR=5 receptor,  either because this is 
nonfunctional for HIV-1 entry or because it is ligated en- 
dogenously  by  the  ~-chemokines  that  are  over-secreted 
from the EU T  cells. 
Many questions on the relationship between the ~-che- 
mokines and HIV-1 replication in vitro and in vivo remain 
unanswered,  but the present paper of Loetscher et al.  ad- 
dresses  a significant issue  (1).  The principal finding in the 
paper is  that  CKR-1  and  CKR-2  are  upregulated  in  re- 
sponse to IL-2 stimulation. IL-4, IL-10, and IL-12 are partial 
activators, whereas several other cytokines are ineffective. 
Triggering of the cells via CD3  or CD28  (or non-specifi- 
cally by PHA)  does  not  upregulate  CKR.-1  and  CKR-2; 
indeed, anti-CD3 or anti-CD28 activation of CKR.-1- and 
CKR.-2-expressing  cells  actually  downregulates  receptor 
expression  (1).  CKR-1,  like  CKR-5,  is  a  MIP-lcx  and 
RANTES receptor (unlike CKR-5, CKR-1 does not bind 
MIP-113  avidly)  (12,  13),  and  it  can function,  albeit to  a 
very  limited  extent,  as  an  HIV-1  second  receptor  (18). 
CKR-2 is a receptor for MCP-1  and MCP-3,  ~-chemo- 
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and does not bind MIP-lot, MIP-113, and R_ANTES (20). 
CKP,-5 expression was not studied in the present paper, (1) 
but  it  is  reasonable  to  speculate  that  its  regulation  in  re- 
sponse to cytokines and mitogens might be broadly similar 
to that of CKR-1 and CKP,-2. Whether and how LESTR 
expression is affected by exogenous stimuli is also unknown 
at present. 
From the perspective of HIV research,  it will be impor- 
tant  to  define  the  relationship  between  the  expression  of 
CKR-5  and  LESTR  and  the  activation  state  of CD4 +  T 
cells.  The  dynamics of HIV-1  replication  are such that  at 
most  1%  of virions come from latently infected  cells  (21- 
23).  It has been suggested that some virus is present in cells 
that became infected while activated but then became qui- 
escent  (24).  It is  unclear,  however,  if HIV-1  can  actually 
infect a resting cell in vivo. Are second receptors for HIV-1 
even  expressed  on quiescent  cells  to  allow  HIV-1  entry? 
The [3-chemokine receptors CKP,.-1, CKk-2, and CKR-3 
are  IL-2-induced  genes  that  are  minimally  expressed  on 
quiescent  CD4 +  T  ceils  (1).  Is  this  true  of CKR-5  and 
LESTR? The SI strain LAI has been reported to enter qui- 
escent cells quite well (25), so an interesting theoretical sce- 
nario is that LESTR. might be constitutively expressed  on 
quiescent  ceils,  permitting  entry  of SI  strains  of HIV-1, 
whereas  CKR.-5  expression  requires  cell activation.  If this 
were the case, SI viruses might have a larger pool of CD4 + 
T  cells in which to replicate under in vivo conditions. Fur- 
thermore,  although factors such as nuclear membrane  dis- 
solution during cell division and upregulation of transcrip- 
tion  factors  such  as  NFkB  are  important  (26,  27),  the 
upregulation of second receptors could also contribute sig- 
nificantly to the increased ability of activated CD4 + T  cells 
to replicate HIV-1. 
A  second  implication  of the  results  of Loetscher  et  al. 
covers T  cell subsets. It has been known for some time that 
CD451<O +  memory  T  cells  are  more  sensitive  than 
CD45RA  + naive T  cells  to the chemoattractant properties 
of the  [3-chemokines,  and memory cells  also secrete more 
[3-chemokines than  naive  cells  (28,  29).  It has  not,  how- 
ever,  been  clear  why.  Furthermore,  several  contradictory 
results  on  this  issue  have  been  reported  in  the  literature. 
Loetscher  et  al.  discuss  several  explanations  of conflicting 
findings, and clarify the situation greatly (1). Their observa- 
tions that the chemotactic responsiveness  of CD4 + T  cells 
depends upon the activation state of the cells,  and hence on 
the degree of 13-chemokine receptor expression, should be 
important  contributions  to  researchers  working  on  lym- 
phocyte chemotaxis.  And there  may also be  an impact of 
these findings on HIV-1 pathogenesis studies, as it is possi- 
ble that CD4 + T  cell subsets  may vary in their patterns  of 
13-chemokine receptor  expression.  Hence  different  CD4 + 
subsets may be differentially susceptible to different HIV-1 
strains,  and this could, in principle,  contribute  to (or even 
account  for)  the  evolution  of the  HIV-1  phenotype  that 
occurs during disease progression (30). It is noteworthy that 
memory T  cells  are preferentially lost during HIV-1 infec- 
tion in vivo (31, 32). 
In summary, the new study from Loetscher et al. will be 
significant  to  established  chemokine  researchers,  and  to 
those  now attracted  towards  these  molecules  by their  in- 
volvement in HIV-1 pathogenesis. 
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